Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This molecule is a natural antisense transcript overlapping and complementary to the SEPT9 gene locus, annotated as ENSG00000267016. Antisense transcripts are non-coding RNAs transcribed from the DNA strand opposite to protein-coding genes. They can regulate the expression of neighboring or overlapping genes through various mechanisms, including transcriptional interference, chromatin modification, RNA masking, and formation of double-stranded RNA that may trigger RNA interference pathways. For SEPT9, a gene implicated in cell division and frequently aberrantly expressed in cancers, the antisense transcript may modulate the level and dynamics of SEPT9 mRNA through chromatin remodeling and epigenetic effects, but its direct function and relevance to human diseases or therapies are not well characterized in the literature. There are no known drugs that specifically target this antisense transcript, and it is not considered a typical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antisense RNA to septin 9 (SEPT9).